Clinical Commander

All dossiers
ob.preterm-labor.v1

Preterm Labor (PTL) / Preterm Prelabor Rupture of Membranes (PPROM)

obstetricsacuteadultpregnancyacuteinpatientoutpatient

NEW Phase C wave 11 dossier — authored 2026-05-15 for shard-5-obped-id. Covers preterm labor (PTL) 20+0 - 36+6 wk + preterm prelabor rupture of membranes (PPROM) variant. Preterm birth ~ 10% of US deliveries; PTL accounts for ~ 40-45%, PPROM ~ 30-35%, indicated preterm birth ~ 25-30%. Recurrence ~ 15-30% in subsequent pregnancy after spontaneous PTB; cervical length < 25 mm at 18-24 wk ~ 6-10% of singleton pregnancies with LR+ ~ 5-8 for preterm birth < 34 wk; PPROM incidence ~ 3% with ~ 30% chorio emergence if expectantly managed < 34 wk. Seed manifest authored at prisma/seed/manifests/ob.preterm-labor.v1.ts (batch-23 scaffold via defineBatch23ScaffoldManifest; sourceWorkupIds: ["preterm_labor"]; ICD-10 / SNOMED / LOINC anchors projected 1:1 from the dossier terminology block — no new codes invented). Status promoted PLANNED → INTEGRATED on the basis of this manifest pointer; citations, RxCUIs, design brief, and workups were authored + verified in prior passes and are unchanged. The companion atoms file (prisma/seed/manifests/ob.preterm-labor.v1.atoms.ts) remains deferred to a dedicated PTL/PPROM atom-authoring pass. _registry.ts NOT modified per refined shard-5 pattern (3-file set only: dossier TS + brief + research bundle). Registry edit deferred to a future shard. Distinct from ob.chorioamnionitis.v1 (sibling — chorio is common PPROM/PTL complication; routes here with PTL/PPROM carryover when fever + Higgins 2016 criteria fire), ob.pre-eclampsia.core.v1 (sibling — PE is leading cause of indicated preterm birth; spontaneous PTL is distinct pathophysiology; magnesium indication overlaps), ob.preeclampsia-early-onset.v1 (sibling — early-onset PE < 34 wk shares 48 h corticosteroid + magnesium-neuroprotection decision pathway), ob.placental-abruption.v1 (sibling — abruption can mimic PTL features but tocolysis CI), id.neonatal-sepsis.early-late.v1 (sibling — preterm + chorio is highest-LR maternal risk profile for EOS). Sibling differentiation explicitly encoded for four. Phenotype matrix (7-axis GA-tier × membrane-status × cervical-length × fFN × prior-preterm-birth × multifetal × pen-allergy cross-product — thousands of cells collapsed to anchor combinations) encoded indirectly via regimen_axes.ptl_pprom_acute_management.steps (tocolysis_nifedipine_first_line / tocolysis_indomethacin_under_32wk_only / tocolysis_terbutaline_short_term_acute_only / magnesium_neuroprotection_under_32_wk / antenatal_corticosteroids_24_to_33_wk / antenatal_corticosteroids_late_preterm_34_to_36_wk / pprom_latency_antibiotics_under_34_wk / gbs_intrapartum_prophylaxis_no_pen_allergy / gbs_iap_pen_allergy_substitute / vaginal_progesterone_asymptomatic_short_cervix) + severity_triggers (10 triggers) + setting playbooks (ed / inpatient / icu / outpatient). First-class TS phenotype field is schema-blocked. Severity triggers (10 — all 10 user-specified): ptl_under_32wk_magnesium_neuroprotection (severe — BEAM 2008 + Doyle 2009; 4-6 g IV load + 1 g/h × 12-24 h), ptl_24_to_34wk_corticosteroid_window (severe — ACOG CO 713 + ALPS 2016; betamethasone or dexamethasone; can extend to 34-36+6 wk for late preterm), pprom_under_34wk_expectant_management (severe — NICHD-MFMU 1997; ampicillin + erythromycin × 7 d AVOID amox-clav; concurrent corticosteroids + magnesium if < 32 wk), pprom_at_or_after_34wk_delivery (moderate — ACOG PB 188 2018 favors delivery; balance RDS vs chorio risk; late preterm steroids per ALPS if no prior course), suspected_chorio_in_pprom_or_ptl (severe — routes to ob.chorioamnionitis.v1; discontinue tocolysis; ampicillin + gentamicin; expedite delivery), cervical_length_under_20mm_at_screening (moderate — Romero 2018 + Hassan 2011; vaginal progesterone 200 mg PV nightly; serial TVUS CL; consider cerclage if prior PTB), tocolytic_indomethacin_under_32wk_only (severe — CONTRAINDICATED ≥ 32 wk; ductus closure + oligohydramnios; switch to nifedipine), prior_preterm_birth_recurrence_prevention (moderate — 15-30% recurrence; vaginal progesterone for short cervix; cerclage per Berghella; 17OHP-C NOT recommended after PROLONG 2019 + FDA withdrawal 2023), placental_abruption_overlap_ptl (life_threatening — routes to ob.placental-abruption.v1; tocolysis CI; emergent delivery + MTP), terbutaline_contraindication_chronic (severe — FDA 2011 BLACK BOX; ≤ 48-72 h hospitalised acute only; never oral or chronic). Bayesian linkage (per §5.5.2): pre-test priors documented in _research-bundles/ob.preterm-labor.v1.md — preterm birth ~ 10% US deliveries (PTL 40-45%, PPROM 30-35%, indicated 25-30%); recurrence ~ 15-30% prior spontaneous PTB; CL < 25 mm at 18-24 wk ~ 6-10% singleton with LR+ ~ 5-8 for PTB < 34 wk; PPROM ~ 3% with ~ 30% chorio emergence if expectant < 34 wk. Key LRs: fFN-negative at 22-34 wk LR- ~ 0.1 for delivery within 7-14 d (high NPV); fFN-positive LR+ ~ 2-3 (modest PPV); cervical length < 15 mm + symptomatic LR+ ~ 8-15 for delivery within 7 d; cervical length < 25 mm at 18-24 wk LR+ ~ 5-8 for PTB < 34 wk; prior preterm birth + similar GA LR+ ~ 3-5 recurrence; PPROM expectantly managed < 34 wk → chorio LR+ ~ 5 (~ 25-30% emergence). Conditional dependencies modeled: GA × tocolytic-efficacy coupling (nifedipine better at 24-33 wk than 34-36 wk where tocolysis controversial); GA × indomethacin-CI coupling (< 32 wk only; ductus risk after); membrane-status × latency-antibiotic-benefit coupling (NICHD-MFMU 1997 shows ≥ 7-day latency effect in PPROM expectant); cervical-length × vaginal-progesterone-benefit coupling (< 20 mm singleton only; not effective for multiples); GBS-status × IAP-coupling (CDC Verani 2010 indications). Decision thresholds: T_tocolysis = 24+0 - 33+6 wk + intact membranes + no contraindication (chorio / abruption / non-reassuring fetal / severe-PE / IUFD); T_magnesium-neuroprotection = < 32+0 wk + imminent delivery; T_corticosteroid-window = 24+0 - 33+6 wk + delivery anticipated within 7 d OR 34+0 - 36+6 wk late preterm + no prior course per ALPS 2016; T_pprom-deliver = ≥ 34+0 wk OR chorio emergence OR non-reassuring fetal status at any GA; T_GBS-IAP = GBS-positive OR unknown-GBS-with-risk-factor (PTL < 37 wk, ROM ≥ 18 h, intrapartum T ≥ 38 °C, prior GBS infant, GBS bacteriuria); T_vaginal-progesterone = asymptomatic CL < 20 mm singleton at 16-24 wk; T_cerclage = history- / US- / exam-indicated per Berghella Cochrane 2017. Cross-dossier routing: ob.chorioamnionitis.v1 (chorio emergence), ob.placental-abruption.v1 (abruption overlay), ob.pre-eclampsia.core.v1 + ob.preeclampsia-early-onset.v1 (PE overlay), id.neonatal-sepsis.early-late.v1 (preterm + chorio newborn pathway), id.sepsis.core.v1 (maternal sepsis via chorio escalation). ROS/DDx LR seed data NOT touched (cross-cutting; not in shard scope). Settings (4): ED (triage symptomatic PTL / PPROM + sterile speculum + TVUS CL + fFN + immediate OB consult + L&D transfer; tertiary transfer if < 32 wk and no NICU), Inpatient L&D / antepartum (definitive PTL / PPROM management; tocolysis + corticosteroids + magnesium + latency abx + GBS IAP; expectant PPROM to 34 wk; chorio surveillance), ICU (rare — maternal sepsis from chorio / pulmonary edema from magnesium+tocolytic+fluid / severe-PE overlay / abruption with hemorrhagic shock / AFE), Outpatient (antepartum surveillance for high-risk; 6-wk postpartum + preconception MFM counseling; mental health + immunization + newborn high-risk peds follow-up). Drug guidance grounded in ACOG PB 234 + 188 + CO 713 + PB 130 + CO 797 + CO 871 + BEAM 2008 + Doyle 2009 + Roberts Cochrane 2017 + ALPS 2016 + NICHD-MFMU 1997 + ORACLE-I 2001 + ORACLE-II 2008 (NEC avoidance) + Hassan 2011 + Romero 2018 + PROLONG 2019 + FDA 2011 (terbutaline black box) + CDC Verani 2010 + Higgins 2016 (chorio overlap). RxCUIs referenced: nifedipine (7417), indomethacin (5781), terbutaline (10368), magnesium sulfate (6585), betamethasone (1514), dexamethasone (3264), ampicillin (733), erythromycin (4053), penicillin G (7980), cefazolin (2180), clindamycin (2582), vancomycin (11124), progesterone (8727), acetaminophen (161), aspirin (1191), norepinephrine (7512), vasopressin (11149), hydrocortisone (5492), furosemide (4603), ferrous sulfate (24947). RxCUIs live-verified against RxNav 2026-05-25 — corrected during citation/RxCUI sweep: terbutaline 10355→10368 (was temazepam), magnesium sulfate 6845→6585 (was methocarbamol), cefazolin 2191→2180 (was ceftazidime), penicillin G 8061→7980 (was invalid), norepinephrine 7980→7512 (7980 was actually penicillin G), ferrous sulfate 4053→24947 (was erythromycin). UNRECOVERABLE: Tdap (1144329, invalid — no clean generic RxNorm concept) and influenza vaccine (1656584, invalid) — bundled ACIP routine-immunization placeholders flagged NEEDS_SOURCE_REVIEW. Open gaps: (1) Phenotype matrix not first-class TS field — schema-blocked. (2) Bayesian LR seed data not encoded — lives in narrative + research bundle only this pass; ROS/DDx seed edit cross-cutting. (3) RESOLVED — seed manifest authored at prisma/seed/manifests/ob.preterm-labor.v1.ts (batch-23 scaffold) and dossier promoted to INTEGRATED. (4) Companion atoms file (prisma/seed/manifests/ob.preterm-labor.v1.atoms.ts) still deferred to a dedicated PTL/PPROM atom-authoring pass. (5) Co-located test file (ob.preterm-labor.test.ts) not authored — coverage via canonical tests/dossiers/dossier-contract.test.ts only. (6) _registry.ts NOT modified per refined shard-5 pattern — registry edit deferred to a future shard. (7) ACOG practice bulletins (e.g., PB 234, PB 188, PB 130, CO 713, CO 797, CO 871) do not carry stable PubMed PMIDs — cited by year + bulletin number; closest indexed PMIDs are the underlying trial papers (BEAM 18753646, Doyle 19160238, Roberts Cochrane 28321847, ALPS 26842679, NICHD-MFMU 9307346, ORACLE-I 11293640, Hassan 21472815, Romero 29157866, PROLONG 31652479, Verani 21088663, Higgins 26855098). (8) Multi-fetal gestation has lower-quality evidence for tocolysis / vaginal progesterone — vaginal progesterone NOT effective per Romero 2018; cerclage controversial. (9) Pessary for short cervix is emerging — evidence mixed; not recommended as first-line. Status INTEGRATED with manifest: "prisma/seed/manifests/ob.preterm-labor.v1.ts" — the audit's "missing manifest pointer" requirement is now satisfied. Open gap (3) above is resolved by this manifest pass; the remaining gaps (phenotype first-class field, Bayesian LR seed encoding, companion atoms file, co-located test file, _registry.ts edit, ACOG-bulletin PMID limitation) persist.

Entry points (8)

  • symptom
    Regular uterine contractions ≥ 4 in 20 min OR ≥ 8 in 60 min between 20+0 and 36+6 wk (ACOG PB 130 2012)
    regular_contractions_at_20_to_37wk
  • symptom
    New low-back ache / pelvic pressure / vaginal pressure at < 37 wk — supportive PTL feature (ACOG PB 130)
    pelvic_pressure_or_low_backache_at_preterm_GA
  • symptom
    Patient reports gush of clear or blood-tinged fluid; speculum shows pooling + nitrazine-positive + ferning OR commercial PPROM assay positive (ACOG PB 188 2018)
    spontaneous_rupture_of_membranes_lt_37wk
  • vital_abnormality
    Cervix ≥ 2 cm dilated OR > 80% effaced on speculum or digital exam at < 37 wk (ACOG PB 130)
    cervical_dilation_or_effacement_at_lt_37wk
  • lab_abnormality
    fFN ≥ 50 ng/mL at 24+0 - 34+6 wk in symptomatic patient with intact membranes — LR+ ~ 2-3 (modest); negative LR- ~ 0.1 high-NPV for delivery within 7-14 d (ACOG PB 130)
    fetal_fibronectin_positive_24_to_34wk
  • imaging
    Transvaginal cervical length < 25 mm (treatment threshold < 20 mm) at 18+0 - 24+6 wk screening — asymptomatic short cervix; vaginal progesterone indicated (Romero meta-analysis AJOG 2018 PMID 29157866; ACOG PB 130)
    transvaginal_cervical_length_under_25mm_at_18_to_24wk
  • history
    Prior spontaneous preterm birth (PTL or PPROM) — recurrence risk ~ 15-30%; high-risk surveillance + intervention (ACOG PB 130)
    prior_spontaneous_preterm_birth_history
  • symptom
    Maternal fever ≥ 39.0 °C single OR 38.0-38.9 °C × 2 ≥ 30 min apart with PTL / PPROM — routes to ob.chorioamnionitis.v1 (Higgins NICHD/ACOG/SMFM 2016 PMID 26855098)
    maternal_fever_with_PTL_or_PPROM

Required inputs (26)

  • maternal_temperaturerequired
    vital • used at RED_FLAGS
    Fever is the trigger for chorio screening (Higgins 2016); ≥ 39.0 °C single OR 38.0-38.9 °C × 2 → routes to ob.chorioamnionitis.v1 with PTL/PPROM carryover
  • maternal_hrrequired
    vital • used at CONTEXT
    Maternal tachycardia > 100 supports chorio; sepsis flag if disproportionate to fever
  • maternal_bprequired
    vital • used at RED_FLAGS
    BP screens for superimposed pre-eclampsia (a major cause of indicated preterm birth) — routes to ob.pre-eclampsia.core.v1
  • maternal_rrrequired
    vital • used at CONTEXT
    Tachypnea > 22 is qSOFA component if sepsis emerging; magnesium toxicity tracked via RR < 12 + DTR loss
  • maternal_spo2required
    vital • used at CONTEXT
    Hypoxemia is unusual in PTL — consider PE / pneumonia / AFE differential
  • fetal_heart_rate_baselinerequired
    vital • used at CONTEXT
    FHR > 160 sustained × 10 min with maternal fever is chorio criterion; FHR baseline + variability informs fetal-status decision
  • gestational_age_weeksrequired
    demographic • used at FRAME
    GA partitions decision branches: < 24 wk periviable counseling; 24+0 - 33+6 corticosteroid window; < 32 wk magnesium neuroprotection; 34+0 - 36+6 late preterm steroids per ALPS 2016; ≥ 37 wk no longer PTL
  • membrane_status_intact_vs_rupturedrequired
    history • used at FRAME
    PTL with intact membranes vs PPROM diverge: PPROM → latency abx (ampicillin + erythromycin × 7 d per NICHD-MFMU 1997) + closer chorio surveillance; PTL with intact membranes → tocolysis + corticosteroid window
  • rom_duration_hoursrequired
    history • used at CONTEXT
    ROM > 18 h is CDC IAP indication + chorio antecedent risk; informs latency-antibiotic decision in PPROM
  • prior_spontaneous_preterm_birth_count_and_GArequired
    history • used at CONTEXT
    Prior preterm birth (especially same or earlier GA) is strongest history risk factor; 15-30% recurrence; informs cerclage indications (history-indicated)
  • cervical_length_at_18_24wk_screeningrequired
    history • used at CONTEXT
    CL < 25 mm (treatment threshold < 20 mm) at 18-24 wk → vaginal progesterone in asymptomatic singleton; informs cerclage decision
  • maternal_gbs_status_and_iap_adequacyrequired
    history • used at TREATMENT
    GBS-positive OR unknown-GBS-with-PTL-or-ROM-risk → IAP penicillin G 5 mU IV load → 2.5-3 mU q4h until delivery (CDC Verani 2010 PMID 21088663 + ACOG CO 797 2020)
  • maternal_pen_allergy_severityrequired
    history • used at TREATMENT
    Anaphylaxis → vancomycin / clindamycin per GBS susceptibility; mild → cefazolin substitute (ACOG CO 797 2020)
  • prior_cerclage_history_or_indication
    history • used at CONTEXT
    History-indicated, US-indicated, or exam-indicated cerclage — current pregnancy decision per Berghella Cochrane 2017
  • maternal_smoking_substance_use
    history • used at CONTEXT
    Smoking and substance use are modifiable PTL risk factors; substance-use disorder informs methadone / buprenorphine planning + naloxone availability
  • multifetal_gestation_statusrequired
    history • used at CONTEXT
    Twin / triplet gestation → very high PTL risk; vaginal progesterone NOT effective for multiples (Romero 2018); cerclage controversial
  • maternal_cbc_with_diffrequired
    lab • used at INITIAL_WORKUP
    WBC > 15K without antenatal steroids supports chorio (Higgins 2016); baseline before steroids + serial trend
  • maternal_blood_culture
    lab • used at INITIAL_WORKUP
    If maternal fever + SIRS / qSOFA features → bacteremia surveillance; routes to id.sepsis.core.v1
  • maternal_urine_culture_and_uarequired
    lab • used at INITIAL_WORKUP
    Asymptomatic bacteriuria and pyelonephritis are PTL triggers — treat to reduce preterm birth (ACOG PB 130)
  • cervicovaginal_swab_GBS_and_chlamydia_gonorrhearequired
    lab • used at INITIAL_WORKUP
    GBS status + chlamydia / gonorrhea screen — STI treatment reduces PPROM and chorio risk
  • fetal_fibronectin_fFN
    lab • used at INITIAL_WORKUP
    fFN at 22+0 - 34+6 wk symptomatic PTL with intact membranes — negative LR- ~ 0.1; positive LR+ ~ 2-3
  • amniotic_fluid_studies_if_amniocentesis
    lab • used at BRANCHING_WORKUP
    Amniocentesis selectively for suspected subclinical IAI — Gram stain, culture, glucose < 14 mg/dL, IL-6 (Higgins 2016 confirmed Triple I criterion)
  • maternal_metabolic_panelrequired
    lab • used at INITIAL_WORKUP
    Renal function for magnesium dosing (toxicity if CrCl < 30); LFTs for HELLP overlap; baseline before tocolysis
  • transvaginal_cervical_length_ultrasoundrequired
    imaging • used at INITIAL_WORKUP
    TVUS CL is the gold-standard cervical assessment; threshold < 25 mm for surveillance, < 20 mm for vaginal progesterone, < 15 mm + symptomatic = very high preterm-birth risk
  • obstetric_ultrasound_growth_and_fluidrequired
    imaging • used at INITIAL_WORKUP
    Confirm GA + EFW + amniotic fluid index (oligohydramnios with indomethacin); placenta location for abruption ddx
  • fetal_doppler_and_efm_continuous_intrapartumrequired
    imaging • used at MONITORING
    Continuous EFM (Category I/II/III) once admitted with PTL or PPROM; umbilical Doppler if growth restriction concern

12-phase flow (12)

  1. 1FRAME
    Preterm labor (PTL) at 20+0 to 36+6 wk gestation defined by regular contractions + cervical change. PPROM is the variant in which membrane rupture precedes / accompanies contractions. Partition by GA tier (periviable 20-23+6 / extreme preterm 24-27+6 / very preterm 28-31+6 / moderate preterm 32-33+6 / late preterm 34-36+6) and membrane status (intact PTL vs PPROM). Distinguishes from term labor (≥ 37 wk; routine), term PROM (≥ 37 wk; ob.prom.v1 if authored, otherwise term PROM management inline), placental abruption (painful bleed + tachysystole; different mechanism), pre-eclampsia indicated preterm birth (BP-driven decision, routes to ob.pre-eclampsia.core.v1 / ob.preeclampsia-early-onset.v1), and Braxton-Hicks (irregular non-progressive contractions without cervical change).
    inputs: gestational_age_weeks, membrane_status_intact_vs_ruptured
    advance: GA tier + membrane status tagged; PTL vs PPROM classification assigned
  2. 2ENTRY
    Recognise PTL via regular contractions ≥ 4 in 20 min OR ≥ 8 in 60 min with cervical change OR cervix ≥ 2 cm dilated at < 37 wk. Recognise PPROM via patient-reported gush + speculum pooling + nitrazine + ferning OR AmniSure / ROM Plus assay positive at < 37 wk. Avoid digital cervical exam in PPROM until delivery anticipated (increases ascending-infection risk).
    inputs: gestational_age_weeks
    advance: PTL or PPROM diagnosed; speculum / TVUS confirmation documented
  3. 3CONTEXT
    GA exact + ROM duration + prior preterm birth history + cervical length screening result + multifetal status + GBS status + IAP adequacy + maternal pen-allergy severity + comorbidities (DM, HTN, smoking, substance use) + prior cerclage. Critical decision context for tocolysis selection, corticosteroid timing, magnesium indication, and delivery-vs-expectant decision (PPROM ≥ 34 wk).
    inputs: gestational_age_weeks, membrane_status_intact_vs_ruptured, rom_duration_hours, prior_spontaneous_preterm_birth_count_and_GA, maternal_gbs_status_and_iap_adequacy, maternal_pen_allergy_severity, multifetal_gestation_status, maternal_hr, maternal_rr, maternal_spo2, fetal_heart_rate_baseline
    advance: Risk-factor profile + GA-tier-specific decision context captured
  4. 4RED_FLAGS
    Maternal fever ≥ 39.0 °C OR 38.0-38.9 °C × 2 + secondary criteria → ob.chorioamnionitis.v1 with PTL/PPROM carryover. Maternal sepsis features (qSOFA ≥ 2 / SIRS ≥ 2 / lactate ≥ 2 / hypotension) → emergent delivery + id.sepsis.core.v1 with OB carryover. Painful vaginal bleeding + tachysystole → ob.placental-abruption.v1. Severe HTN ≥ 160/110 → ob.preeclampsia-early-onset.v1. Non-reassuring FHR Category III → emergent delivery. PROM with prolapsed cord → emergent cesarean.
    inputs: maternal_temperature, maternal_bp, maternal_hr, fetal_heart_rate_baseline
    actions: protocol.septic_shock
    advance: Red-flag routing decisions documented (chorio / sepsis / abruption / severe-PE / fetal Cat III / cord-prolapse)
  5. 5INITIAL_WORKUP
    Maternal CBC + CMP (renal for magnesium dosing), urine culture + UA (asymptomatic bacteriuria / pyelonephritis), cervicovaginal GBS + chlamydia / gonorrhea swabs, fFN (intact membranes 22-34 wk if symptomatic), TVUS cervical length, obstetric US for growth + fluid + placenta location. Continuous EFM once admitted. Speculum confirmation if PPROM suspected. Document GA tier exactly (24+0 / 28+0 / 32+0 / 34+0 / 36+6 are decision-tier boundaries).
    inputs: maternal_cbc_with_diff, maternal_metabolic_panel, maternal_urine_culture_and_ua, cervicovaginal_swab_GBS_and_chlamydia_gonorrhea, transvaginal_cervical_length_ultrasound, obstetric_ultrasound_growth_and_fluid
    actions: workup.preeclampsia, panel.cbc, panel.renal, panel.ua
    advance: Diagnostic labs + imaging drawn; GA tier confirmed; risk-stratification ready
  6. 6BRANCHING_WORKUP
    Branching by GA tier + membrane status + risk-stratification result. Periviable 20-23+6 wk: counseling on neonatal viability + maternal risks + termination consideration. 24-31+6 wk PTL or PPROM: full tocolysis + corticosteroid + magnesium + IAP. 32-33+6 wk: tocolysis + corticosteroid + IAP (NO magnesium ≥ 32 wk). 34-36+6 wk PPROM: deliver (induction or expectant per local protocol — ACOG PB 188 favors delivery). 34-36+6 wk PTL intact: late-preterm steroids per ALPS 2016 if no prior course + delivery anticipated within 7 d; tocolysis controversial here (limited efficacy). Amniocentesis selectively for suspected subclinical IAI (chorio without clinical fever).
    inputs: amniotic_fluid_studies_if_amniocentesis, maternal_blood_culture
    actions: workup.fuo
    advance: GA-tier-specific treatment plan documented; branching decisions complete
  7. 7DIFFERENTIAL
    Braxton-Hicks (irregular, non-progressive, no cervical change), placental abruption (painful bleed + tachysystole + tender uterus → ob.placental-abruption.v1; tocolysis CONTRAINDICATED), chorioamnionitis (fever + Higgins 2016 → ob.chorioamnionitis.v1; tocolysis contraindicated in confirmed chorio), pre-eclampsia with indicated preterm birth (BP ≥ 140/90 + proteinuria → ob.preeclampsia-early-onset.v1 if < 34 wk), urinary tract infection (asymptomatic bacteriuria / pyelonephritis can present with contractions — treat per UA / culture), gastroenteritis with cramping (vital signs + GI features), round ligament pain (unilateral, sharp, related to movement; benign), term PROM (≥ 37 wk; routine).
    advance: Mimics excluded or co-managed; tocolysis contraindications ruled out
  8. 8RISK_STRATIFICATION
    GA tier + cervical length + fFN + symptom severity + prior preterm birth history drive imminence: very-high-risk (CL < 15 mm + fFN-positive + symptomatic) → expedited admission + full intervention; moderate-risk (CL 15-25 mm + fFN-positive OR negative + symptomatic) → admit + intervene; low-risk (CL ≥ 25 mm + fFN-negative + symptomatic) → discharge with return precautions (LR- ~ 0.1 for delivery within 7-14 d). PPROM at any GA always full admission + intervention.
    inputs: gestational_age_weeks, fetal_fibronectin_fFN, transvaginal_cervical_length_ultrasound
    actions: calc.qsofa, calc.sirs
    advance: Imminence tier set; admit-vs-discharge decision documented
  9. 9TREATMENT
    TOCOLYSIS (24+0 - 33+6 wk PTL with intact membranes; NOT for chorio / abruption / non-reassuring fetal status): nifedipine 20-30 mg PO load → 10-20 mg q4-6h (max 180 mg/day) is first-line (calcium-channel blocker; reduces preterm birth + improves neonatal outcome; preferred over indomethacin and terbutaline). Indomethacin 50-100 mg PO load → 25-50 mg q6h × 48 h is alternative ONLY at < 32 wk (oligohydramnios + ductal closure risk after 32 wk). Atosiban (EU only; oxytocin receptor antagonist). Terbutaline 0.25 mg SC q20 min × 3 doses for ACUTE short-term tocolysis only (FDA black box restricts chronic use; cardiac death risk). MAGNESIUM NEUROPROTECTION (< 32 wk PTL or PPROM): 4-6 g IV load over 20-30 min + 1 g/h × 12-24 h (BEAM NEJM 2008 PMID 18753646; Doyle Cochrane 2009 PMID 19160238). CORTICOSTEROIDS (24+0 - 33+6 wk: betamethasone 12 mg IM q24h × 2 doses OR dexamethasone 6 mg IM q12h × 4 doses; 34+0 - 36+6 wk late preterm if delivery anticipated < 7 d + no prior course: betamethasone same regimen per ALPS NEJM 2016 PMID 26842679). PPROM LATENCY ANTIBIOTICS (< 34 wk): ampicillin 2 g IV q6h × 48 h then amoxicillin 250 mg PO q8h × 5 d + erythromycin 250 mg IV q6h × 48 h then 333 mg PO q8h × 5 d (NICHD-MFMU PPROM trial Mercer JAMA 1997 PMID 9307346); AVOID amoxicillin-clavulanate (NEC risk per ORACLE-II Kenyon 2008). GBS IAP intrapartum: penicillin G 5 mU IV load → 2.5-3 mU q4h until delivery (or ampicillin 2 g + 1 g q4h; cefazolin 2 g + 1 g q8h mild pen-allergy; vancomycin / clindamycin per GBS susceptibility for severe pen-allergy — CDC Verani 2010 PMID 21088663 + ACOG CO 797 2020). VAGINAL PROGESTERONE for asymptomatic short cervix < 20 mm at 16-24 wk: 200 mg PV nightly through 36+6 wk. CERCLAGE for history-indicated (≥ 3 prior 2nd-tri losses or preterm births) or US-indicated (prior preterm birth + current CL < 25 mm) or exam-indicated (dilation in 2nd tri without contractions; cerclage may help) per Berghella Cochrane 2017.
    inputs: gestational_age_weeks, membrane_status_intact_vs_ruptured, maternal_gbs_status_and_iap_adequacy, maternal_pen_allergy_severity
    advance: Tocolysis (if indicated), corticosteroids, magnesium (if < 32 wk), latency antibiotics (if PPROM), and IAP plan documented and started
  10. 10DISPOSITION
    L&D / antepartum unit for active PTL or PPROM (most admissions). Periviable counseling consultation if 20-23+6 wk. ICU only if maternal sepsis / pulmonary edema / multi-organ dysfunction. Transfer to tertiary center if < 32 wk and current facility lacks NICU. Outpatient cervical-length surveillance + vaginal progesterone for asymptomatic short cervix at < 24 wk. Discharge symptomatic intact-membrane PTL with negative fFN + CL ≥ 25 mm + arrested progression after 4-6 h observation with return precautions and close follow-up.
    inputs: gestational_age_weeks, maternal_bp, maternal_spo2
    advance: Maternal level of care set; NICU coordination if delivery imminent; tertiary-transfer decision if indicated
  11. 11MONITORING
    Continuous EFM intrapartum (Category I/II/III); maternal vitals q15 min during active labor or magnesium loading; q1 h post-load; q4 h stable. Magnesium toxicity surveillance: hourly DTRs + RR + UO (toxicity if RR < 12 / DTR loss / UO < 0.5 mL/kg/h; calcium gluconate 1 g IV antidote). Daily CBC + CMP if expectantly managing PPROM. Maternal temperature q4 h (chorio surveillance). PPROM amniotic fluid volume serial US weekly. Cervical length serial if expectant PTL. Continuous EFM during corticosteroid administration + magnesium load (transient fetal-heart-rate variability reduction expected).
    inputs: maternal_temperature, maternal_hr, maternal_rr, fetal_heart_rate_baseline, fetal_doppler_and_efm_continuous_intrapartum
    actions: panel.cbc, panel.renal
    advance: Maternal-fetal status stable + no chorio emergence + tocolysis effective (48 h achieved) OR delivered with appropriate neonatal coordination
  12. 12FOLLOWUP
    6-week postpartum visit + preterm-birth-specific anticipatory guidance: recurrence ~ 15-30% in subsequent pregnancy; preconception MFM consult for next pregnancy planning (early CL surveillance, vaginal progesterone planning, cerclage indication review per Berghella Cochrane 2017). Mental health screen (EPDS for postpartum depression; PCL-5 for peripartum PTSD especially after extreme preterm or NICU outcomes). Contraception counseling + interpregnancy interval ≥ 18 mo. Immunization audit (Tdap, flu, COVID per ACIP). Newborn outpatient peds visit 24-48 h post-discharge if late preterm; first-year developmental tracking if very preterm or extreme preterm (cerebral palsy + BPD + IVH risk monitoring per AAP NRN framework).
    advance: Postpartum visit complete; preconception MFM counseling delivered; mental health + immunization + newborn developmental tracking arranged